MedTrace Logo

Antihypertensive Deprescribing in Long-term Care

NCT05047731 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 522

Last updated 2026-01-08

No results posted yet for this study

Summary

Frail older adults are commonly prescribed blood pressure medication, yet it is unclear if blood pressure medication is actually beneficial for them. Observational studies in this population suggest blood pressure medication has limited benefit and may even be harmful, including an increased risk for falls and cognitive impairment. Randomized controlled trials are needed to confirm this.

This study is a randomized controlled trial of blood pressure medication deprescribing, amongst long-term care residents with systolic blood pressure lower than 135 mmHg. In the intervention group, with physician consent, the facility pharmacist or nurse practitioner will continually reduce antihypertensives provided an upper systolic threshold of 145 mmHg is not exceeded. The control group will receive usual care. The hypothesis is that avoiding unnecessarily low systolic blood pressure is beneficial in a frail, end-of-life population.

Conditions

Interventions

DRUG

Antihypertensive medication

Antihypertensive medication will be continually reduced provided an upper systolic threshold of 145 mmHg is not exceeded

Sponsors & Collaborators

  • Alberta Health services

    collaborator OTHER

  • University of Alberta

    lead OTHER

Principal Investigators

  • Roni Kraut · University of Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2025-11-30
Completion
2025-11-30

Countries

  • Canada

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05047731 on ClinicalTrials.gov